C-peptide and long-term complications of diabetes

Pediatric Diabetes

Volumn 12, Issue 3 PART 2, 2011, Pages 276-292

  Luppi, Patrizia ^a   Cifarelli, Vincenza ^a   Wahren, John ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

C peptide; Nephropathy; Neuropathy; Signaling; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); C PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NITRIC OXIDE;

BLOOD FLOW; DIABETES MELLITUS; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; C-PEPTIDE; CELL MEMBRANE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NITRIC OXIDE; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION;

EID: 79955376981     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2010.00729.x     Document Type: Review

References (121)

1. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967: 157: 697-700.
2. Polonsky K, O'Meara N. Secretion and metabolism of insulin, proinsulin and C-peptide. In: DeGroot L, Jameson J, eds. Endocrinology. Philadelphia, PA: WB Saunders, 2001: 697-711.
3. Henriksson M, Nordling E, Melles E et al. Separate functional features of proinsulin C-peptide. Cell Mol Life Sci 2005: 62: 1772-1778.
4. Kitabchi AE. Proinsulin and C-peptide: a review. Metabolism 1977: 26: 547-87.
5. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes 1984: 33: 486-94.
6. Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987: 30: 208-213.
7. Zerbini G, Mangili R, Luzi L. Higher post-absorptive C-peptide levels in Type 1 diabetic patients without renal complications. Diabet Med 1999: 16: 1048.
8. Panero F, Novelli G, Zucco C et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009: 32: 301-305.
9. Fiorina P, Folli F, Zerbini G et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003: 14: 2150-2158.
10. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998: 339: 69-75.
11. Conrad B, Weidmann E, Trucco G et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 1994: 371: 351-355.
12. Goodier MR, Nawroly N, Beyan H, Hawa M, Leslie RD, Londei M. Identical twins discordant for type 1 diabetes show a different pattern of in vitro CD56+ cell activation. Diabetes Metab Res Rev 2006: 22: 367-75.
13. Wilson SB, Kent SC, Patton KT et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998: 391: 177-81.
14. Adler T, Akiyama H, Herder C, Kolb H, Burkart V. Heat shock protein 60 elicits abnormal response in macrophages of diabetes-prone non-obese diabetic mice. Biochem Biophys Res Commun 2002: 294: 592-596.
15. Beyan H, Goodier MR, Nawroly NS et al. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes 2006: 55: 3439-3445.
16. Hanenberg H, Kolb-Bachofen V, Kantwerk-Funke G, Kolb H. Macrophage infiltration precedes and is a prerequisite for lymphocytic insulitis in pancreatic islets of pre-diabetic BB rats. Diabetologia 1989: 32: 126-34.
17. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009: 5: 219-26.
18. Schalkwijk CG, Poland DC, van Dijk W et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999: 42: 351-7.
19. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med 2000: 248: 67-76.
20. Devaraj S, Cheung AT, Jialal I et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007: 56: 2790-2796.
21. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006: 55: 774-779.
22. Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol 2002: 56: 522-529.
23. Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel Namiduru E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001: 34: 645-650.
24. Cifarelli V, Libman IM, Deluca A, Becker D, Trucco M, Luppi P. Increased expression of monocyte cd11b (mac-1) in overweight recent-onset type 1 diabetic children. Rev Diabet Stud 2007: 4: 112-117.
25. Schram MT, Chaturvedi N, Schalkwijk C et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 2003: 26: 2165-2173.
26. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003: 46: 1402-1407.
27. Kim JA, Berliner JA, Natarajan RD, Nadler JL. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 1994: 43: 1103-1107.
28. Morigi M, Angioletti S, Imberti B et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 1998: 101: 1905-1915.
29. Haubner F, Lehle K, Munzel D, Schmid C, Birnbaum DE, Preuner JG. Hyperglycemia increases the levels of vascular cellular adhesion molecule-1 and monocyte-chemoattractant-protein-1 in the diabetic endothelial cell. Biochem Biophys Res Commun 2007: 360: 560-565.
30. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988: 12: 365-372.
31. De Caterina R, Libby P, Peng HB Jr et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995: 96: 60-68.
32. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991: 43: 109-142.
33. Kimura C, Oike M, Ito Y. Acute glucose overload abolishes Ca2+ oscillation in cultured endothelial cells from bovine aorta: a possible role of superoxide anion. Circ Res 1998: 82: 677-685.
34. Kimura C, Oike M, Koyama T, Ito Y. Impairment of endothelial nitric oxide production by acute glucose overload. Am J Physiol Endocrinol Metab 2001: 280: E171-E178.
35. Wallerath T, Kunt T, Forst T et al. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003: 9: 95-102.
36. Scalia R, Coyle KM, Levine BJ, Booth G, Lefer AM. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J 2000: 14: 2357-2364.
37. Kitamura T, Kimura K, Makondo K et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003: 46: 1698-1705.
38. Ekberg K, Johansson B-L, Wahren J. Stimulation of blood flow by C-peptide in patients with type 1 diabetes. Diabetologia 2001: 44 (Suppl 1): A323.
39. Johansson BL, Wahren J, Pernow J. C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab 2003: 285: E864-E870.
40. Fernqvist-Forbes E, Johansson BL, Eriksson MJ. Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. Acta Physiol Scand 2001: 172: 159-165.
41. Johansson BL, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992: 35: 1151-1158.
42. Lindström K, Johansson C, Johnsson E, Haraldsson B. Acute effects of C-peptide on the microvasculature of isolated perfused skeletal muscles and kidneys in rat. Acta Physiol Scand 1996: 156: 19-25.
43. Forst T, Kunt T, Pohlmann T et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998: 101: 2036-2041.
44. Johansson BL, Sjoberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992: 35: 121-128.
45. Cotter MA, Ekberg K, Wahren J, Cameron NE. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003: 52: 1812-1817.
46. Hansen A, Johansson BL, Wahren J, von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002: 51: 3077-3082.
47. Johansson BL, Sundell J, Ekberg K et al. C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab 2004: 286: E14-E19.
48. Tooke JE. Microvascular function in human diabetes: a physiological perspective. Diabetes 1995: 44: 721-726.
49. McMillan DE, Utterback NG, La Puma J. Reduced erythrocyte deformability in diabetes. Diabetes 1978: 27: 895-901.
50. Ernst E, Matrai A. Altered red and white blood cell rheology in type II diabetes. Diabetes 1986: 35: 1412-1415.
51. Forst T, De La Tour DD, Kunt T et al. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+, K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 2000: 98: 283-290.
52. Young LH, Ikeda Y, Scalia R, Lefer AM. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2000: 279: H1453-H1459.
53. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 2008: 51: 1534-1543.
54. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001: 107: 7-11.
55. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 2008: 201: 248-257.
56. Sima AA, Zhang W, Kreipke CW, Rafols JA, Hoffman WH. Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 2009: 6: 37-42.
57. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 2005: 54: 1497-1505.
58. Al-Rasheed NM, Chana RS, Baines RJ, Willars GB, Brunskill NJ. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 2004: 279: 49747-49754.
59. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000: 101: 235-238.
60. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005: 123: 993-999.
61. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008: 102: 283-294.
62. Vish MG, Mangeshkar P, Piraino G et al. Proinsulin C-peptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med 2007: 35: 1348-1355.
63. Greene D, Sima AA, Feldman E, Stevens M. Diabetic neuropathy. In: Porte D Jr, Robert S S, eds. Ellenberg and Rifkin Diabetes Mellitus, 5th edn. Stanford: Appleton & Lange, 1997: 1009-1076.
64. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ III, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester diabetic neuropathy study cohort. Diabetes Care 1999: 22: 1479-1486.
65. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005: 54: 1615-1625.
66. Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003: 60: 2445-2464.
67. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
68. Sima AA, Bril V, Nathaniel V et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988: 319: 548-555.
69. Cherian PV, Kamijo M, Angelides KJ, Sima AA. Nodal Na(+)-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W rat: prevention by aldose reductase inhibition. J Diabetes Complications 1996: 10: 192-200.
70. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988: 81: 349-364.
71. Murakawa Y, Zhang W, Pierson CR et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab Res Rev 2002: 18: 473-483.
72. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003: 52: 536-541.
73. Ekberg K, Brismar T, Johansson BL et al. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007: 30: 71-76.
74. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000: 17: 181-189.
75. Brown MJ, Bird SJ, Watling S et al. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 2004: 27: 1153-1159.
76. Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996: 39: 687-695.
77. Sima AA, Zhang W, Sugimoto K et al. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia 2001: 44: 889-897.
78. Sima AA, Zhang W, Li ZG, Murakawa Y, Pierson CR. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 2004: 53: 1556-1563.
79. Stevens MJ, Zhang W, Li F, Sima AA. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004: 287: E497-E505.
80. Ido Y, Vindigni A, Chang K et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997: 277: 563-566.
81. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997: 40: 271-281.
82. Brismar T, Sima AA. Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: potential clamp analysis. Acta Physiol Scand 1981: 113: 499-506.
83. Sima AA, Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 1985: 18: 21-29.
84. Sima AA, Lattimer SA, Yagihashi S, Greene DA. Axo-glial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat. J Clin Invest 1986: 77: 474-484.
85. Sima AA, Zhang W, Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004: 5: 65-77.
86. Dyck PJ, Lambert EH, O'Brien PC. Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 1976: 26: 466-471.
87. Kamiya H, Zhang W, Sima AA. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004: 56: 827-835.
88. Fioretto P, Steffes MW, Brown DM, Mauer SM. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 1992: 20: 549-558.
89. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005: 28: 164-176.
90. Osterby R. Renal pathology in diabetes mellitus. Curr Opin Nephrol Hypertens 1993: 2: 475-483.
91. Johansson BL, Kernell A, Sjoberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993: 77: 976-981.
92. Sjöquist M, Huang W, Johansson BL. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 1998: 54: 758-764.
93. Samnegard B, Jacobson SH, Jaremko G, Johansson BL, Sjoquist M. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001: 60: 1258-1265.
94. Huang DY, Richter K, Breidenbach A, Vallon V. Human C-peptide acutely lowers glomerular hyperfiltration and proteinuria in diabetic rats: a dose-response study. Naunyn Schmiedebergs Arch Pharmacol 2002: 365: 67-73.
95. Samnegard B, Jacobson SH, Jaremko G et al. C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant 2005: 20: 532-538.
96. Nordquist L, Brown R, Fasching A, Persson P, Palm F. Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol 2009: 297: F1265-F1272.
97. Nordquist L, Lai EY, Sjoquist M, Patzak A, Persson AE. Proinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism. Am J Physiol Regul Integr Comp Physiol 2008: 294: R836-R841.
98. Kamikawa A, Ishii T, Shimada K et al. Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev 2008: 24: 331-338.
99. Ohtomo Y, Aperia A, Sahlgren B, Johansson BL, Wahren J. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996: 39: 199-205.
100. Tsimaratos M, Roger F, Chabardes D et al. C-peptide stimulates Na+, K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia 2003: 46: 124-131.
101. Maezawa Y, Yokote K, Sonezaki K et al. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev 2006: 22: 313-322.
102. Hills CE, Al-Rasheed N, Willars GB, Brunskill NJ. C-peptide reverses TGF-beta1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy. Am J Physiol Renal Physiol 2009: 296: F614-F621.
103. Flatt PR, Swanston-Flatt SK, Hampton SM, Bailey CJ, Marks V. Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumor. Biosci Rep 1986: 6: 193-199.
104. Pramanik A, Ekberg K, Zhong Z et al. C-peptide binding to human cell membranes: importance of Glu27. Biochem Biophys Res Commun 2001: 284: 94-98.
105. Rigler R, Pramanik A, Jonasson P et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 1999: 96: 13318-13323.
106. Lindahl E, Nyman U, Melles E et al. Cellular internalization of proinsulin C-peptide. Cell Mol Life Sci 2007: 64: 479-486.
107. Lindahl E, Nyman U, Zaman F et al. Proinsulin C-peptide regulates ribosomal RNA expression. J Biol Chem 2010: 285: 3462-3469.
108. Luppi P, Geng X, Cifarelli V, Drain P, Trucco M. C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia 2009: 52: 2218-2228.
109. Shafqat J, Juntti-Berggren L, Zhong Z et al. Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular cells. Cell Mol Life Sci 2002: 59: 1185-1189.
110. Zhong Z, Kotova O, Davidescu A et al. C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci 2004: 61: 2782-2790.
111. Al-Rasheed NM, Meakin F, Royal EL et al. Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia 2004: 47: 987-997.
112. Grunberger G, Qiang X, Li Z et al. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001: 44: 1247-1257.
113. Walcher D, Aleksic M, Jerg V et al. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes 2004: 53: 1664-1670.
114. Kitamura T, Kimura K, Jung BD et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J 2001: 355: 123-129.
115. Kitamura T, Kimura K, Jung BD et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J 2002: 366: 737-744.
116. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003: 19: 375-385.
117. Zierath JR, Handberg A, Tally M, Wallberg-Henriksson H. C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation. Diabetologia 1996: 39: 306-313.
118. De La Tour DD, Raccah D, Jannot MF, Coste T, Rougerie C, Vague P. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia 1998: 41: 1080-1084.
119. Kunt T, Schneider S, Pfutzner A et al. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type I diabetes mellitus. Diabetologia 1999: 42: 465-471.
120. Shafqat J, Melles E, Sigmundsson K et al. Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects. Cell Mol Life Sci 2006: 63: 1805-1811.
121. Wahren J, Ekberg K, Shafqat J, Johansson J, Johansson B-L, Jornvall H. Biological effects of C-peptide and proinsulin. In: DeFronzo R, Ferrannini E, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, 3rd edn. San Francisco, CA, USA: John Wiley, 2005: 165-181.